Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]

Details

Serval ID
serval:BIB_A124D4D50BD9
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Journal
Revue medicale suisse
Author(s)
Arangalage D., Pavon A.G., Hugelshofer S., Desgraz B., Tzimas G., Delyon J., Muller O., Obeid M., Ribi C., Michielin O., Özdemir B.C., Monney P.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
03/06/2020
Peer-reviewed
Oui
Volume
16
Number
696
Pages
1165-1168
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Immune checkpoint inhibitors (ICI) have revolutionized the field of oncology, by reshaping the prognosis of many cancers and are progressively becoming the standard of care. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), of which cardiovascular irAEs are particularly feared. ICI-induced myocarditis is often a diagnostic challenge because of the vast heterogeneity of clinical presentations, and it is associated with a high mortality rate of around 50%. The present article summarizes the cardiac manifestations, the diagnostic strategy and the therapeutic management of patients with ICI-induced myocarditis used in the treatment of cancer.
Keywords
Cardiotoxicity/etiology, Humans, Immunotherapy/adverse effects, Myocarditis/chemically induced, Neoplasms/drug therapy, Neoplasms/immunology, Neoplasms/pathology
Pubmed
Create date
10/06/2020 20:47
Last modification date
03/07/2020 6:26
Usage data